Lab or animal research
Pinealon primary study · PMID 21978084
Cultured cerebellar granule cells, neutrophils and PC12 cells.
Reported findings. The experimental peptide affected reactive oxygen species and cell survival in these models.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Cell viability is not evidence of improved memory, neuroprotection or longevity in patients.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Clinical observation
Pinealon/Vesugen: small clinical observation report (2015)
Report states 32 adults aged 41–83 with polymorbidity and organic brain syndrome in remission; Pinealon and Vesugen were studied.
Reported findings. Authors reported anabolic effects and improvements in CNS activity and biological-age indicators with Pinealon and Vesugen. These are attributed observations, not established lifespan gains.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Authors also reported pro-oxidant activity and reduced CD34-positive hematopoietic markers, interpreted by them as inhibition of hematopoiesis. These are biological concerns in mixed-preparation observations, not established Pinealon-specific clinical injury rates.
Limits. Mixed preparations, unclear allocation/blinding and abstract participant-count inconsistencies. Biological-age surrogates do not establish lifespan benefit or safety.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.